Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsInterplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCIAssociation of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis.Advances in the monitoring of anti-P2Y12 therapy.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence?CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.Clopidogrel, CYP2C19, and a Black Box.Genetic testing in antiplatelet therapy - not effective for perioperative bleeding.Clopidogrel in Critically Ill Patients.Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes.The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy.
P2860
Q26775125-C6608DE8-72C4-4150-8F19-4847342103BBQ33933475-36ABDA37-AAE4-4579-AAC1-3D9661B6BE86Q35208684-907F689B-90DB-4C63-AA7E-063D41BEE259Q35764145-EF281659-6E77-4B86-855F-473B5EBB285AQ35951677-A7659854-143A-4354-A35A-984A3B74EEAEQ37694929-B8A97D25-64E4-47C5-B0C7-A285FA837125Q38037121-7B8EFA17-853A-4B75-8AC8-A81B406D4EB1Q38177048-792178CE-13E2-42B8-91D1-FE48D9A514CCQ38307535-EBC36A10-1816-402B-A99B-7F7CD80A22CFQ38817051-96166382-6500-42AD-9CA4-E8785EE0646CQ38958862-47668D24-EC26-429F-B48B-D80127382A3FQ40366712-A2C87B31-A976-44DA-9B14-30566950B53EQ41574497-46D4C76F-884E-43BB-98B7-D19293BC9B03Q43710350-4E51F78C-66B4-45E0-AF1B-010E1D85DDB1Q44442043-6CE6CB2A-AD0C-4040-971B-FD2813A0D1F2Q44906555-7977DDD6-6223-4068-8BA8-F16DE81FAAD6Q45342015-6E899A79-429F-4229-8F41-C5C38BE994C1Q47160727-2C6E9C16-6212-4817-8285-290144135EA8Q47980408-B1A37F5E-63A6-4D11-8B63-0E045B53E507Q48689443-AF8ED36E-0063-4840-8985-A96E87802D4CQ48737764-4815F05E-E635-4633-87C3-0668E2BCD3CEQ51063040-A7029A26-08C0-43F1-A386-410C6D006A83Q51749154-3C11F886-6CAE-4005-9F3A-46AA16BBDE04Q54073059-291DC1E4-59FE-485C-9EAC-FF5B30C629FF
P2860
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
description
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2012
@uk
name
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@en
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@nl
type
label
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@en
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@nl
prefLabel
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@en
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@nl
P2093
P2860
P50
P1476
Phenotyping vs. genotyping for ...... safety: the PEGASUS-PCI study
@en
P2093
G Delle-Karth
K Linkowska
M Kozinski
T Grzybowski
T Neunteufl
P2860
P304
P356
10.1111/J.1538-7836.2012.04639.X
P577
2012-04-01T00:00:00Z